Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UROPOT: Metabolic Potentiation of Aminoglycosides for UTI Prevention
NCT05761405Phase 1Recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amikacin and Bronchitol in urinary tract infection (UTI) (3 arms), sponsored by Lausanne University Hospital. Primary endpoint: Infection prophylaxis at 48 hours. Started Jan 2024; status: recruiting.
02
Drugs
amikacinBronchitol
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT05761405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761405.